Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y, Kawanami D. Muta Y, et al. Among authors: chin k. Front Pharmacol. 2024 Mar 27;15:1358573. doi: 10.3389/fphar.2024.1358573. eCollection 2024. Front Pharmacol. 2024. PMID: 38601470 Free PMC article.
Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
Kobayashi K, Toyoda M, Kimura M, Hatori N, Furuki T, Sakai H, Takihata M, Umezono T, Ito S, Suzuki D, Takeda H, Kanamori A, Degawa H, Yamamoto H, Machimura H, Mokubo A, Chin K, Obana M, Hishiki T, Aoyama K, Nakajima S, Umezawa S, Shimura H, Aoyama T, Sato K, Miyakawa M. Kobayashi K, et al. Among authors: chin k. Diab Vasc Dis Res. 2019 Jan;16(1):103-107. doi: 10.1177/1479164118802759. Epub 2018 Oct 4. Diab Vasc Dis Res. 2019. PMID: 30284913 Free article.
Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring.
Kobayashi K, Toyoda M, Kimura M, Hatori N, Furuki T, Sakai H, Takihata M, Umezono T, Ito S, Suzuki D, Takeda H, Kanamori A, Degawa H, Yamamoto H, Machimura H, Mokubo A, Chin K, Obana M, Hishiki T, Aoyama K, Nakajima S, Umezawa S, Shimura H, Aoyama T, Sato K, Miyakawa M. Kobayashi K, et al. Among authors: chin k. Clin Exp Hypertens. 2019;41(7):637-644. doi: 10.1080/10641963.2018.1529778. Epub 2018 Oct 29. Clin Exp Hypertens. 2019. PMID: 30373408
Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease.
Kobayashi K, Toyoda M, Kaneyama N, Hatori N, Furuki T, Sakai H, Takihata M, Umezono T, Ito S, Suzuki D, Takeda H, Kanamori A, Degawa H, Yamamoto H, Machimura H, Mokubo A, Chin K, Obana M, Hishiki T, Aoyama K, Nakajima S, Umezawa S, Shimura H, Aoyama T, Miyakawa M. Kobayashi K, et al. Among authors: chin k. J Diabetes Res. 2019 Nov 3;2019:9415313. doi: 10.1155/2019/9415313. eCollection 2019. J Diabetes Res. 2019. PMID: 31781668 Free PMC article.
Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
Kobayashi K, Toyoda M, Hatori N, Furuki T, Sakai H, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Yamamoto H, Machimura H, Chin K, Hishiki T, Takihata M, Aoyama K, Umezawa S, Minamisawa K, Aoyama T, Hamada Y, Suzuki Y, Hayashi M, Hatori Y, Sato K, Miyakawa M, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: chin k. J Diabetes Investig. 2021 Jan;12(1):74-81. doi: 10.1111/jdi.13318. Epub 2020 Jul 10. J Diabetes Investig. 2021. PMID: 32506833 Free PMC article.
Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kobayashi K, Toyoda M, Hatori N, Saito N, Kanaoka T, Sakai H, Furuki T, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Yamamoto H, Machimura H, Chin K, Hishiki T, Takihata M, Aoyama K, Umezawa S, Minamisawa K, Aoyama T, Hamada Y, Suzuki Y, Hayashi M, Hatori Y, Sato K, Miyakawa M, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: chin k. Diabetes Technol Ther. 2021 Feb;23(2):110-119. doi: 10.1089/dia.2020.0165. Epub 2020 Aug 13. Diabetes Technol Ther. 2021. PMID: 32721227
Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Chin K, Kimura M, Saito N, Kanaoka T, Aoyama T, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Machimura H, Hishiki T, Umezawa S, Shimura H, Nakajima S, Yamamoto H, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: chin k. Diabetes Res Clin Pract. 2022 Mar;185:109231. doi: 10.1016/j.diabres.2022.109231. Epub 2022 Feb 5. Diabetes Res Clin Pract. 2022. PMID: 35131376
Cross-sectional survey of hypertension management in clinical practice in Japan: the Kanagawa Hypertension Study 2021 conducted in collaboration with Japan Medical Association Database of Clinical Medicine.
Kobayashi K, Chin K, Hatori N, Furuki T, Sakai H, Miyakawa M, Asayama K, Eguchi N, Katsuya T, Tamura K, Sato K, Kanamori A. Kobayashi K, et al. Among authors: chin k. Hypertens Res. 2023 Nov;46(11):2447-2459. doi: 10.1038/s41440-023-01366-z. Epub 2023 Aug 2. Hypertens Res. 2023. PMID: 37532949
2,273 results